|
| 特征 |
后续注入denosumab |
| < 5个月 |
5 - 7个月 |
> 7个月 |
|
| 样本大小() |
12 |
365年 |
59 |
| 年龄、年,意味着(SD) |
67.50 (9.59) |
68.35 (10.62) |
64.34 (11.20) |
| 女性,% () |
91.67% (11) |
92.6% (338) |
91.53% (54) |
| 质子泵抑制剂(PPI)使用% () |
27.27% (3) |
26.30% (96) |
22.03% (13) |
| 选择性5 -羟色胺再摄取抑制剂(SSRI), % () |
0.00% (0) |
6.85% (25) |
7.02% (4) |
| Serotonin-norepinephrine再摄取抑制剂(去甲肾上腺素重摄取抑制剂)使用% () |
0.00% (0) |
1.37% (5) |
5.17% (3) |
| 三环抗抑郁药(TCA)使用% () |
9.09% (1) |
4.11% (15) |
5.17% (3) |
| BMD,意味着(SD) |
|
|
|
| 腰椎 |
0.850 (0.149) |
0.800 (0.131) |
0.808 (0.101) |
| 股骨颈 |
0.629 (0.043) |
0.623 (0.100) |
0.619 (0.100) |
| nonvertebral骨折史,% () |
41.67% (5) |
55.34% (202) |
49.15% (29) |
| 椎骨折史,% () |
16.67% (2) |
23.56% (86) |
22.05% (13) |
|
|
